Nucala is the first anti-IL5 biologic to be licensed in the United States for at-home administration and the first respiratory biologic to be approved for administration via an autoinjector.
The FDA is seeking comments on the potential public health impact of making fixed-quantity unit-of-use blister packages of certain opioid pain medications as well as which products are good candidates for blister packaging.
MerckManuals.com features a more prominent search box, a “letter spine” for locating health topics and medical conditions alphabetically and quick links to other health information.